Christina Yao

- **Total net revenues** for Concord Medical in the first half of 2025 were **RMB200.6 million (US$28.0 million)**, representing an **8.3% decrease** from RMB218.8 million in the same period last year.  **[1472072_0001104659-25-093565_tm2526644d1_ex99-1.htm:0]** 
- The company reported a **gross loss of RMB4.3 million (US$0.6 million)** in the first half of 2025, a significant improvement from a gross loss of RMB41.6 million in the first half of 2024, with the gross loss margin improving from 19.0% to **2.1%**.  **[1472072_0001104659-25-093565_tm2526644d1_ex99-1.htm:0]** 
- **Net loss attributable to ordinary shareholders** for the first half of 2025 was **RMB27.1 million (US$3.8 million)**, a substantial improvement compared to RMB172.3 million in the same period last year.  **[1472072_0001104659-25-093565_tm2526644d1_ex99-1.htm:0]** 
- **Basic and diluted loss per share** for Class A and Class B ordinary shares was **RMB0.21 (US$0.03)** in the first half of 2025, compared to RMB1.31 in the same period last year.  **[1472072_0001104659-25-093565_tm2526644d1_ex99-1.htm:0]** 
- The improvement in financial results was primarily driven by an **11.1% increase in hospital business net revenues** due to the commencement of proton therapy operations, despite a **41.3% decrease in network business net revenues** due to decreased demand and non-renewal of operating lease contracts.  **[1472072_0001104659-25-093565_tm2526644d1_ex99-1.htm:1]**

Concord Medical Reports First Half 2025 Financial Results

- Concord Medical reported **total net revenues of RMB200.6 million (US$28.0 million)** for the first half of 2025, representing an **8.3% decrease** from the same period last year.  **[1472072_20250926CN84173:0]** 
- The company significantly **reduced its net loss attributable to ordinary shareholders to RMB27.1 million (US$3.8 million)** in the first half of 2025, compared to RMB172.3 million in the first half of 2024.  **[1472072_20250926CN84173:0]** 
- **Basic and diluted loss per share improved to RMB0.21 (US$0.03)** for the first half of 2025, down from RMB1.31 in the prior year period.  **[1472072_20250926CN84173:0]** 
- **Adjusted EBITDA improved to negative RMB62.2 million (US$8.7 million)** in the first half of 2025, compared to negative RMB148.0 million in the same period last year.  **[1472072_20250926CN84173:0]** 
- **Hospital business net revenues increased by 11.1% to RMB153.0 million (US$21.4 million)**, mainly due to the commencement of proton therapy operations, while **network business net revenues decreased by 41.3% to RMB47.6 million (US$6.6 million)**.  **[1472072_20250926CN84173:1]**

Concord Medical Services Holdings (CCM)